Popular GLP-1 receptor agonist medications—widely prescribed for weight management and type 2 diabetes under brand names such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Trulicity—have been linked to an unexpected side effect involving fingernails, hair, and scalp health. According to a multinational study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026, individuals taking these blockbuster therapies were more than four times as likely to report nail detachment, a clinical condition where the fingernail separates from the underlying nail bed.
The findings mark the first controlled scientific investigation into the potential relationship between GLP-1 medications and nail health. Researchers discovered that 39% of GLP-1 users experienced nail detachment, compared with just 9% of control participants who had never taken the medications. Furthermore, nail discoloration was considerably more common among the treatment group, with two-thirds (66%) of users reporting at least one form of nail disorder overall.
Unexpected Nail Problems Among GLP-1 Users
Over recent years, GLP-1 receptor agonists have transformed the medical landscape for managing obesity and type 2 diabetes. By acting on a complex hormone signaling system that helps regulate blood sugar levels and suppress appetite, these medications have proven to be exceptionally effective tools for improving metabolic health and supporting substantial weight loss. Millions of patients worldwide now rely on them to address chronic metabolic conditions.
However, as the global footprint of these drugs expands, medical researchers are casting a wider net to investigate their potential systemic effects on other parts of the body. Until recently, clinical understanding regarding nail changes during GLP-1 treatment relied primarily on anecdotal evidence and individual reports of adverse reactions rather than rigorous, controlled comparisons.
To bridge this knowledge gap and establish clearer data, researchers conducted a comprehensive study examining 575 individuals using GLP-1 medications and compared them against a control group of 1,329 individuals who suffered from type 2 diabetes and/or obesity but had never used the drugs. To ensure a diverse and representative sample, study participants were recruited across multiple countries, including France, the United States, Brazil, and Mexico.
The results revealed a consistent and statistically significant pattern. Overall, 66% of participants taking GLP-1 medications reported experiencing at least one nail disorder, compared with 53% of individuals in the control group. Nail discoloration showed an especially stark contrast, affecting 46% of medication users versus only 17% of nonusers. Nail detachment was even more striking, with reported cases running more than four times as common among those actively taking GLP-1 therapies.
Weight Loss Alone May Not Explain the Nail Changes
A critical question facing researchers was whether these nail complications were simply an indirect consequence of rapid weight loss rather than a direct pharmacological effect of the medications themselves. Significant and sudden shifts in body weight can heavily impact nutritional status, metabolic equilibrium, and various physiological processes, all of which are known to influence the health and structural integrity of nails and hair.
Nevertheless, the research team discovered that weight loss alone could not fully account for the observed discrepancies. Even when statisticians limited their analysis strictly to participants who had successfully lost weight, GLP-1 users continued to report significantly higher rates of nail problems than individuals who had lost weight through other means without the help of these medications.
"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said study author Dr. Charles Taïeb. "Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself."
The researchers carefully emphasized that their cross-sectional findings do not definitively prove that GLP-1 drugs directly cause nail disorders. Notably, approximately half of the medication users surveyed stated they had experienced various nail problems even before initiating their treatment regimens.
When researchers adjusted their statistical models to account for pre-existing skin conditions and underlying nutritional deficiencies, some of the numerical gaps between the medication and control groups narrowed. Even so, nail detachment and discoloration remained approximately two to three times more common among GLP-1 users after these comprehensive adjustments were made.
Scientists Also Find Higher Rates of Hair Loss and Scalp Problems
The unexpected dermatological findings extended well beyond fingernails. A companion study evaluating the exact same multinational cohort identified significant and widespread differences in hair and scalp health among individuals utilizing GLP-1 medications.
Half of the GLP-1 users reported unusual hair loss, compared with 34% of the nonusing control group. Reduced hair volume and lower overall density were also substantially more common, affecting 42% of medication users versus 19% of individuals who had never taken the drugs.
When researchers focused specifically on hair loss that began after treatment was initiated, the numbers remained compelling. Post-treatment shedding was reported by 26% of GLP-1 users, compared with 12% of nonusers, making it more than twice as frequent in the medication cohort. Furthermore, scalp redness was observed to be approximately three times more common among those taking GLP-1 therapies.
One of the more clinically intriguing discoveries was that hair loss rarely appeared as an isolated symptom. The vast majority of users who reported hair shedding also suffered from concurrent scalp symptoms, including persistent itching, skin redness, or flaking skin.
These accompanying manifestations raised the distinct possibility that localized inflammation could be contributing to the observed changes, rather than the hair loss being explained entirely by the classic telogen effluvium typically triggered by rapid weight reduction.
"This suggests that what is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," explained study author Dr. Bruno Halioua. "Scalp inflammation was the rule rather than the exception, which clinicians do not currently look for and which may be treatable. Taken together, our findings suggest that factors beyond weight loss alone may contribute to the hair, scalp and nail changes observed among GLP-1 users."
What the Findings Mean for People Taking GLP-1 Drugs
Despite the relatively high frequency of reported symptoms, the investigators strongly stressed that their findings should prompt clinical awareness and vigilance rather than unwarranted public alarm or discontinuation of vital therapies.
"These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one’s own initiative," Dr. Halioua noted, advising that anyone who notices unusual hair shedding, an itchy or red scalp, or noticeable nail changes should bring the symptoms up with their treating physician rather than abruptly halting their medication schedule.
Researchers also pointed out important methodological limitations to keep in mind. Both investigations were cross-sectional studies, meaning they captured a snapshot of participants’ experiences at a single point in time without tracking them prospectively to observe how symptoms developed over the course of treatment. Additionally, the findings relied heavily on subjective symptoms reported directly by participants rather than standardized, objective clinical examinations performed by dermatologists.
Consequently, while the studies successfully reveal clear statistical patterns and associations, they cannot definitively prove whether GLP-1 medications directly caused the reported nail, hair, or scalp issues.
To explore these complex questions with greater precision, the research team is already planning prospective studies designed to follow patients from the very beginning of their treatment journeys. These upcoming investigations will incorporate standardized skin, hair, and nail examinations, alongside comprehensive biological monitoring.
The ultimate objective of this ongoing research is to establish exactly when structural changes first appear, identify the underlying biological mechanisms driving them, and determine whether these dermatological symptoms naturally improve or resolve over time.
The research received institutional support from DUCRAY Laboratories, a division of the Pierre Fabre Group specializing in dermatological and hair care products developed to help manage skin and scalp conditions and improve patient quality of life.